Management Team

Prior to founding PainReform in 2007, Mr. Teleman was a senior Business Development officer at Pharmos, a company focused on the research and development of novel CB2 receptor agonists for the treatment of neuropathic and inflammatory pain. At Pharmos, Dan was responsible for building strategic alliances with other pharmaceutical companies and in-licensing additional products.

Prior to Pharmos, Mr. Teleman held marketing and sales positions at Amgen working on Enbrel, a $4 billion drug. Prior to Amgen, Dan served as an officer in one of Israel Defense Forces R&D unit.

Mr. Teleman holds an MBA from the Duke University-Fuqua School of Business and an M.Sc. in Biotechnology from the Ben Gurion University of the Negev.

Dr. Cooper has enjoyed a long and successful career in both academia and the pharmaceutical industry.

From 1995-2005, he served as a Senior Vice President of Clinical and Medical Affairs at Wyeth Consumer Healthcare, where he designed the clinical development plans for Advil Liquigels, Advil Allergy and Sinus and Advil PM.

He also holds patents for various analgesic combination products. He currently is a Board member of the Eastern Pain Association.

Dr. Cooper is most well-known as the developer of the Dental Impaction Pain Model, one of the most widely used pain models in the world. He has published in peer reviewed journals over 100 clinical papers on a wide variety of analgesic drugs.